Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051267 | 0.93 | MAPT (0.44) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL20652707 | 0.88 | ROCK2 (0.48) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL23418021 | 0.88 | ROCK2 (0.48) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL20652858 | 0.87 | ROCK2 (0.48) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL20652589 | 0.86 | ROCK2 (0.47) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL23391734 | 0.85 | TBXAS1 (0.52) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL31104422 | 0.85 | TBXAS1 (0.52) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL23418227 | 0.84 | ROCK2 (0.46) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL23418272 | 0.84 | ROCK2 (0.46) | ROCK2MAPTNPY5RKIF11TBXAS1 | |
| SCHEMBL20652942 | 0.84 | KDM4E (0.50) | ROCK2MAPTNPY5RKIF11TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652329-B1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2019014429-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | UBQLN1, UBQLN2, CRBN | ROCK2 3748/4885MAPT 4/4885NPY5R 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.